Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

A. Corso, S. Mangiacavalli, L. Barbarano, L. Montalbetti, A. Mazzone, S. Fava, M. Varettoni, P. Zappasodi, E. Morra, M. Lazzarino

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

Original languageEnglish
Pages (from-to)1085-1090
Number of pages6
JournalLeukemia Research
Volume32
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Thalidomide
Multiple Myeloma
Dexamethasone
Transplants
Melphalan
Therapeutics
Heart Rate

Keywords

  • High-dose therapy
  • Intensification
  • Multiple myeloma
  • Thalidomide
  • Up-front therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. / Corso, A.; Mangiacavalli, S.; Barbarano, L.; Montalbetti, L.; Mazzone, A.; Fava, S.; Varettoni, M.; Zappasodi, P.; Morra, E.; Lazzarino, M.

In: Leukemia Research, Vol. 32, No. 7, 07.2008, p. 1085-1090.

Research output: Contribution to journalArticle

@article{8182e5f5b0324b2796ddcdd38e4f0f3c,
title = "Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy",
abstract = "Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6{\%}, VGPR 40{\%}, PR 23{\%}, MR 23{\%}, and progression 8{\%}. The response rate after Thal-Dex were similar: CR 11{\%}, VGPR 39{\%}, PR 17{\%}, MR 9{\%}, and progression 24{\%}. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.",
keywords = "High-dose therapy, Intensification, Multiple myeloma, Thalidomide, Up-front therapy",
author = "A. Corso and S. Mangiacavalli and L. Barbarano and L. Montalbetti and A. Mazzone and S. Fava and M. Varettoni and P. Zappasodi and E. Morra and M. Lazzarino",
year = "2008",
month = "7",
doi = "10.1016/j.leukres.2007.11.011",
language = "English",
volume = "32",
pages = "1085--1090",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy

AU - Corso, A.

AU - Mangiacavalli, S.

AU - Barbarano, L.

AU - Montalbetti, L.

AU - Mazzone, A.

AU - Fava, S.

AU - Varettoni, M.

AU - Zappasodi, P.

AU - Morra, E.

AU - Lazzarino, M.

PY - 2008/7

Y1 - 2008/7

N2 - Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

AB - Giving the impact of complete response (CR) on outcome of multiple myeloma patients addressed to high-dose melphalan, we explored the role of a pre-transplant intensification with 3 months thalidome plus dexamethasone therapy (Thal-Dex), after pulse-VAD induction. Seventy-four multiple myeloma patients (MM pts) uniformly treated, were retrospectively studied. The response rate after pulse-VAD were: CR 6%, VGPR 40%, PR 23%, MR 23%, and progression 8%. The response rate after Thal-Dex were similar: CR 11%, VGPR 39%, PR 17%, MR 9%, and progression 24%. Giving no advantage in terms of response rate with an additive toxicity, Thal-Dex does not seem useful for intensification before transplant.

KW - High-dose therapy

KW - Intensification

KW - Multiple myeloma

KW - Thalidomide

KW - Up-front therapy

UR - http://www.scopus.com/inward/record.url?scp=41949136010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949136010&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.11.011

DO - 10.1016/j.leukres.2007.11.011

M3 - Article

C2 - 18096226

AN - SCOPUS:41949136010

VL - 32

SP - 1085

EP - 1090

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -